Showing 1 - 6 results of 6 for search 'Thomas Mehrling', query time: 0.03s Refine Results
  1. 1
    Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy

    Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy by Thomas Mehrling, Daniel Soltis

    Published 2018-02-01
    Get full text
    Article
  2. 2
    Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11

    Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11 by Thomas Mehrling, Daniel Soltis, the Antibodies Editorial Office

    Published 2018-08-01
    Get full text
    Article
  3. 3
    The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

    The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma by Claudio Festuccia, Andrea Mancini, Alessandro Colapietro, Giovanni Luca Gravina, Flora Vitale, Francesco Marampon, Simona Delle Monache, Simona Pompili, Loredana Cristiano, Antonella Vetuschi, Vincenzo Tombolini, Yi Chen, Thomas Mehrling

    Published 2018-02-01
    Get full text
    Article
  4. 4
    Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

    Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair by Ana-Alicia López-Iglesias, Ana B. Herrero, Marta Chesi, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Irena Misiewicz-Krzeminska, Dalia Quwaider, Montserrat Martín-Sánchez, Daniel Primo, Teresa Paíno, P. Leif Bergsagel, Thomas Mehrling, Marcos González-Díaz, Jesús F. San-Miguel, María-Victoria Mateos, Norma C. Gutiérrez, Mercedes Garayoa, Enrique M. Ocio

    Published 2017-06-01
    Get full text
    Article
  5. 5
    Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies

    Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies by Radhia M’kacher, Monika Frenzel, Mustafa Al Jawhari, Steffen Junker, Corina Cuceu, Luc Morat, Anne-Laure Bauchet, Lev Stimmer, Aude Lenain, Nathalie Dechamps, William M. Hempel, Geraldine Pottier, Leonhard Heidingsfelder, Eric Laplagne, Claire Borie, Noufissa Oudrhiri, Dima Jouni, Annelise Bennaceur-Griscelli, Bruno Colicchio, Alain Dieterlen, Theodore Girinsky, Raphael Boisgard, Jean Bourhis, Jacques Bosq, Thomas Mehrling, Eric Jeandidier, Patrice Carde

    Published 2018-10-01
    Get full text
    Article
  6. 6
    Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity

    Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity by Evan R. Abt, Khalid Rashid, Thuc M. Le, Suwen Li, Hailey R. Lee, Vincent Lok, Luyi Li, Amanda L. Creech, Amanda N. Labora, Hanna K. Mandl, Alex K. Lam, Arthur Cho, Valerie Rezek, Nanping Wu, Gabriel Abril-Rodriguez, Ethan W. Rosser, Steven D. Mittelman, Willy Hugo, Thomas Mehrling, Shanta Bantia, Antoni Ribas, Timothy R. Donahue, Gay M. Crooks, Ting-Ting Wu, Caius G. Radu

    Published 2022-08-01
    Get full text
    Article

Search Tools: